A study in healthy men to test how BI 474121 is tolerated

Safety, tolerability, and pharmacokinetics of single rising oral doses of BI 474121 in healthy Japanese male subjects (doubleblind, randomised, placebo-controlled, parallel group design)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2071210040

Enrollment

Registered

2021-07-07

Start date

2021-07-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer disease and Cognitive impairment associated with schizophrenia

Interventions

Investigational medicine : BI 474121(dose: 2.5 mg/5 mg/10 mg/20 mg)oral medication or Other: Placebo oral medication

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure[BP], PR) including body temperature, 12-lead ECG, and clinical laboratory tests at screening visit

Exclusion criteria

Exclusion criteria: Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator at screening visit

Design outcomes

Primary

Measure	Time frame
Percentage of subjects with drug-related adverse events	—

Secondary

Measure	Time frame
AUC0and Cmax of BI 474121	—

Contacts

Public ContactAiko Watabe

Boehringer Ingelheim

ctinfo@boehringer-ingelheim.com+81-120-189-779

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026